PART I Our Business We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. Our business strategy includes leve...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-012240 | EDGAR | 87K words |
| 2025-02-25 | 2024-12-31 | 0001628280-25-007715 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001628280-24-007205 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0001628280-23-005259 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001171843-22-001460 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001171843-21-001411 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001171843-20-001710 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001171843-19-001727 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001171843-18-001855 | EDGAR | — |
| 2017-02-27 | 2016-12-31 | 0001171843-17-001159 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001628280-25-048785 | EDGAR | 61K words |
| 2025-08-05 | 2025-06-30 | 0001628280-25-037795 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001628280-25-022658 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001628280-24-045364 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001628280-24-035170 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001628280-24-021069 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001628280-23-037847 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001628280-23-027820 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016458 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0001628280-22-028463 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0001628280-22-021373 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001171843-22-003423 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001171843-26-001119 | EDGAR | 5K words |
| 2026-01-23 | 0001140361-26-002200 | EDGAR | — |
| 2026-01-12 | 0001171843-26-000213 | EDGAR | — |
| 2026-01-09 | 0001171843-26-000154 | EDGAR | — |
| 2025-12-12 | 0001171843-25-007909 | EDGAR | — |
| 2025-12-11 | 0001171843-25-007878 | EDGAR | — |
| 2025-12-03 | 0001140361-25-044110 | EDGAR | — |
| 2025-11-03 | 0001171843-25-006881 | EDGAR | — |
| 2025-10-14 | 0001140361-25-038031 | EDGAR | — |
| 2025-10-01 | 0001140361-25-036875 | EDGAR | — |
259 total filings indexed. 227 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000882796 |
| Ticker | BCRX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.biocryst.com |
| Listed | 1994-03-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report